DE69731646D1 - Verabreichung von nukleinsäurepartikeln - Google Patents

Verabreichung von nukleinsäurepartikeln

Info

Publication number
DE69731646D1
DE69731646D1 DE69731646T DE69731646T DE69731646D1 DE 69731646 D1 DE69731646 D1 DE 69731646D1 DE 69731646 T DE69731646 T DE 69731646T DE 69731646 T DE69731646 T DE 69731646T DE 69731646 D1 DE69731646 D1 DE 69731646D1
Authority
DE
Germany
Prior art keywords
administration
nucleic acid
acid particles
particles
nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69731646T
Other languages
English (en)
Other versions
DE69731646T2 (de
Inventor
Lee Burkoth
Gordon Muddle
Maree Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Research Ltd
Original Assignee
Powderject Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Research Ltd filed Critical Powderject Research Ltd
Publication of DE69731646D1 publication Critical patent/DE69731646D1/de
Application granted granted Critical
Publication of DE69731646T2 publication Critical patent/DE69731646T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69731646T 1996-09-11 1997-09-11 Verabreichung von nukleinsäurepartikeln Expired - Fee Related DE69731646T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9619002.0A GB9619002D0 (en) 1996-09-11 1996-09-11 Particle delivery
GB9619002 1996-09-11
PCT/GB1997/002478 WO1998010750A2 (en) 1996-09-11 1997-09-11 Nucleic acid particle delivery

Publications (2)

Publication Number Publication Date
DE69731646D1 true DE69731646D1 (de) 2004-12-23
DE69731646T2 DE69731646T2 (de) 2005-12-01

Family

ID=10799793

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69731646T Expired - Fee Related DE69731646T2 (de) 1996-09-11 1997-09-11 Verabreichung von nukleinsäurepartikeln

Country Status (7)

Country Link
EP (1) EP0928190B1 (de)
JP (1) JP2001500858A (de)
AU (1) AU4307997A (de)
DE (1) DE69731646T2 (de)
ES (1) ES2234016T3 (de)
GB (1) GB9619002D0 (de)
WO (1) WO1998010750A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
ATE235890T1 (de) 1997-01-30 2003-04-15 Chiron Corp Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
CA2345945A1 (en) 1998-10-01 2000-04-13 Powderject Research Limited Spray coated microparticles for use in needleless syringes
US6881723B1 (en) 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
CN1230152C (zh) * 1999-02-03 2005-12-07 鲍德杰克特研究有限公司 水凝胶颗粒制剂
US7022320B1 (en) 1999-02-09 2006-04-04 Powderject Vaccines, Inc. Mycobacterium tuberculosis immunization
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
ES2278786T3 (es) 2000-09-28 2007-08-16 Novartis Vaccines And Diagnostics, Inc. Composiciones de microparticulas y procedimientos de fabricacion de las mismas.
GB0103620D0 (en) * 2001-02-14 2001-03-28 Prometic Biosciences Ltd Sterile composition and its preparation
EP2179729B1 (de) 2003-06-02 2016-07-20 GlaxoSmithKline Biologicals SA Immunogene zusammensetzungen auf basis von mikropartikeln, enthaltend ein adsorbiertes toxoid und ein polysaccharid-enthaltendes antigen
CA2537184A1 (en) * 2003-08-29 2005-03-10 Anges Mg, Inc. Gene therapy for skin disorders using needleless syringes
CA2702340C (en) 2006-10-12 2014-12-16 The University Of Queensland Compositions and methods for modulating immune responses
DE102007004855B4 (de) * 2007-01-31 2014-03-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Vorrichtung und Verfahren zur Deposition von biologischem Material in einem Zielsubstrat
DK2222697T3 (da) 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunsuppressive polypeptider og nukleinsyrer
CN103328499A (zh) 2010-11-01 2013-09-25 悉尼科技大学 免疫调节剂及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6707194A (en) * 1993-04-19 1994-11-08 Medisorb Technologies International L.P. Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression
GB9612629D0 (en) * 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery

Also Published As

Publication number Publication date
JP2001500858A (ja) 2001-01-23
EP0928190B1 (de) 2004-11-17
EP0928190A2 (de) 1999-07-14
GB9619002D0 (en) 1996-10-23
ES2234016T3 (es) 2005-06-16
AU4307997A (en) 1998-04-02
DE69731646T2 (de) 2005-12-01
WO1998010750A3 (en) 1998-06-25
WO1998010750A2 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
DE69633974D1 (de) Nachweis von nukleinsäure-variationen
DE69832490D1 (de) Vervielfältigung von nukleinsäuren
ATE239011T1 (de) Neuartige form von s-omeprazol
ID30075A (id) Partikel gel superserap multikomponen
DE69913553D1 (de) Konfigurierung von systemeinheiten
DE69731646D1 (de) Verabreichung von nukleinsäurepartikeln
DE69837906D1 (de) Insektizides proteintoxin von xenorhabus
DE69611102D1 (de) Verstärkung der mutagenese von nukleinsäuren
DE69727986D1 (de) Erkennung von extravasation
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
DE69715801T2 (de) Granuläre Zusammensetzungen von E-pthalimido-Peroxyhexansäure
ID25722A (id) Penganalisa partikel-partikel padat terlarut
DE69921311D1 (de) Vervielfältigung von nukleinsäuren
DE69518743T2 (de) Modifizierung von nukleotidanalogen
ATE232397T1 (de) Neuartige orale zubereitungen von calcitonin
DE69606053T2 (de) Modifizierte fluorsulfonsäure
PT878467E (pt) Acidos 6-aminotetra-hidroisoquinolinacarboxilicos e 7-aminotetra-hidroisoquinolinacarboxilicos substituidos
ID24700A (id) Partikel hidroksiapatit berpori sebagai pembawa bahan obat
DE69623593T2 (de) Feststoffe enthaltend valproinsäure und natriumvalproat
DK0925273T3 (da) Farmaceutiske præparater indeholdende 4-oxo-butansyrer
DE69709159D1 (de) Kreuz-dimierisierung von olefinen
DE69722623D1 (de) Verabreichungssystem von funktionellen wirkstoffen
NO995388D0 (no) Fremgangsmåte for fremstilling av formylfosfonsyre
DE69840475D1 (de) Verbessertes fällungsverfahren von 7-aminocephalosporansäure
DE69610739D1 (de) Umwandlung von substituierten 8-Chlorochinolinen in substituierte 8-Hydroxychinoline

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee